Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Hodgkin lymphoma -- new characteristics discovered

Hodgkin lymphoma -- new characteristics discovered

October 09, 2008

Cytokines help tumor cells evade the immune system

Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern. The phenotype and the characteristics of Hodgkin lymphoma cells are therefore unique. Björn Lamprecht and Dr. Stephan Mathas (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch and Charité - Universitätsmedizin Berlin, Germany) have demonstrated the production of interleukin 21 (IL-21) in the tumor cells of Hodgkin lymphoma. IL-21, a signaling molecule (cytokine) of the immune system, promotes the growth of cancer cells and helps them evade immune system detection (Blood*, Vol. 112. N0. 8, 2008, 3339-3347).




Until now IL-21 was thought to be produced only by T cells, another group of immune cells. Blocking IL-21 production could lead to the development of new therapy strategies for Hodgkin lymphoma in the future, according to the researchers in Professor Bernd Dörken's laboratory, who collaborated with researchers at the University Tor Vergata, Rome (Italy).

It was not until 1994, some 160 years after Hodgkin's lymphoma (HL) was first described by the British physician Thomas Hodgkin (1832), that - using molecular biological methods - scientists discovered that the disease originates from the white blood cells, the B cells. They noticed, however, that the malignant Hodgkin/Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL) exhibit a phenotype and characteristics that are considerably altered. Although HRS cells are derived from B cells, they have lost the expression of most of the B cell genes due to reprogramming.

The research hypothesis of the just-published paper was that the tumor cells, due to the loss of many B-cell specific genes, need alternative signaling pathways to maintain their malignant growth. As Dr. Mathas explained, "Reprogramming can provide the cells of Hodgkin ymphoma with this survival advantage." Hence, the researchers were searching for factors that normally do not originate from B cells. They found what they were looking for in the gene for the cytokine IL-21.

Different Functions of IL-21

It has only been a few years since IL-21 was discovered in T cells. The function of IL-21, however, varies greatly depending on the kind of cell. In some cell types IL-21 stimulates the body's protection program, which researchers call programmed cell death or apoptosis. Each cell contains this apoptosis program so that it will self-destruct when it is altered or defective. This prevents the defective cell from damaging the entire organism.

Thus, IL-21 stimulates the T cells of the immune system and, for instance, drives cells of the chronic-lymphatic leukemia of the B-cell type (B-CLL) to apoptosis. By contrast, in T-cell leukemias, IL-21 does just the opposite and stimulates malignant growth. For the first time, the researchers from Berlin and Rome were able to show that IL-21 is produced by lymphatic cells originally derived from B cells. IL-21 activates a specific signaling pathway (STAT3), thus up-regulating the expression of a group of specific genes in HRS cells which support the unchecked growth and survival of HRS cells.

IL-21 also activates a chemoattractant for cells which suppress the immune system

On top of that, according to further findings of the researchers, IL-21 activates a protein (MIP-3 alpha) in the HRS cells that attracts a group of T cells to the tumor which suppress the immune system. In the healthy organism, these regulatory T cells keep the immune system in check and prevent excessive immune responses.

In proximity to the HRS cells there are a large number of these regulatory T cells. Attracted by MIP-3-alpha, they can suppress an effective immune defense of the body against the HRS cells. The production of such chemoattractants could, according to the researchers, also be a cause for why Hodgkin lymphoma contains so few tumor cells. They comprise merely 0.1 to one percent of the tissue.

Animal experiments have shown that in immunological diseases like rheumatoid arthritis and lupus erythematosus, a disease accompanied by symptoms such as skin changes and inflammation of blood vessels and joints, these symptoms can be significantly improved if IL-21 is inhibited. "If we could block IL-21 or also MIP-3 alpha in human tumor cells," Dr. Mathas added, "this might be a new therapeutic approach for Hodgkin lymphoma." The present cure rate for the disease - also in its advanced stages - is 80 to 90 percent, particular when chemotherapy is used. However, these therapy regimens might have severe side ffects including the risk of therapy-induced secondary malignancies.

Helmholtz Association of German Research Centres



Related Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News Articles Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News RSS Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News RSS
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

New therapy prevents dangerous side effect for lymphoma patients
Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Novel treatments show improvements in survival and response rates for leukemia and lymphoma
The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse.

Novel therapeutic approaches may improve patient outcomes in several platelet disorders
Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood.

New ovarian stimulation technique offers more cancer patients the chance to preserve their fertility
Researchers have shown for the first time that it is possible to stimulate a woman's ovaries to produce eggs for collection during the final phase of the menstrual cycle.

Adding epratuzumab to standard therapy
Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma.

USC researchers find new clues to risk of Hodgkin lymphoma
A long-term study of twins has led University of Southern California (USC) researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein (interleukin-12).

Attention: Extra-hepatic manifestation of hepatitis C virus infection
In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV).

Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
Scientists at Thomas Jefferson University Hospital and Jefferson's Kimmel Cancer Center have received approval for a first-of-its kind study on the effect high dose vitamin C has on non-Hodgkin lymphoma patients.

Quantitative PET Imaging Finds Early Determination of Effectiveness of Cancer Treatment
With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient's response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors.
More Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News Articles


The Official Patient's Sourcebook on Adult Non-Hodgkin's Lymphoma: A Revised and Updated Directory for the Internet Age
by Icon Health Publications

This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to adult non-hodgkin's lymphoma (also Cancer non-Hodgkin's lymphoma;...



Hodgkin Lymphoma

The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET...



Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options
by Lorraine Johnston

Prior to publication of this resource guide, no book on the market targeted the non-Hodgkin's lymphoma survivor's need for understandable information. While there are medical texts on the non-Hodgkin's lymphomas as well as inspirational first-person accounts from survivors of related cancers such as leukemia, between these two sources of information existed a considerable information gap. In...



Non-Hodgkin's Lymphomas: A Self-Study Program

Harvard Medical School, Boston, MA. Provides information on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin's lymphomas, reflecting a multidisciplinary approach. Each disease includes coverage on the clinical evaluation and selection of treatment. Abundant color illustrations. For physicians and residents. DNLM: Lymphomas,...

Non-Hodgkin's Lymphomas: New Insights and Therapeutic Strategies, An Issue of Hematology/Oncology Clinics (The Clinics: Internal Medicine)
by Bruce Cheson

Non-Hodgkin's Lymphoma (NHL) is defined as any of a large group of cancers of the immune system. NHL's can occur at any age and patients are often marked by enlarged lymph nodes, fever, and weight loss. There are many different types of non-Hodgkin lymphoma, which can be divided into aggressive (fast-growing) and indolent (slow-growing) types and can be classified as either B-cell or T-cell...

Non-Hodgkin's lymphomas in children (Masson monographs in pediatric hematology/oncology)



Hodgkin's and Non-Hodgkin's Lymphoma (Cancer Treatment and Research)

Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets,...



Pediatric Lymphomas (Pediatric Oncology)

The book covers the epidemiology, pathology, molecular biology, clinical features, diagnosis, and treatment of Hodgkin and non-Hodgkin lymphomas in children and adolescents. It is a combined effort of investigators who are leaders in the field of childhood lymphomas. Introductory chapters on Hodgkin and non-Hodgkin lymphomas in children provide a concise historical overview. All chapters have a...



Non-Hodgkin Lymphoma Medical Guide
by Qontro Medical Guides

The Non-Hodgkin Lymphoma Medical Guide is a publication which has been designed to better help readers understand Non-Hodgkin Lymphoma. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Non-Hodgkin Lymphoma. The Non-Hodgkin Lymphoma Medical Guide is highly recommended for those interested...

Hodgkin Lymphoma: Studies of Advanced Stages, Relapses & the Relation to Non-Hodgkin Lymphomas (Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, 1132)
by Rose-Marie Amini

© 2009 BrightSurf.com